- Home
- WHF vs UNCY Comparison
WHF vs UNCY Comparison
Compare WHF & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | UNCY |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.1M | 150.1M |
| IPO Year | 2012 | 2021 |
Fundamental Metrics
Financial Performance| Metric | WHF | UNCY |
|---|---|---|
| Price | $7.05 | $5.49 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.75 | ★ $25.67 |
| AVG Volume (30 Days) | 46.5K | ★ 776.2K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 13.67% | N/A |
| EPS Growth | ★ 31.91 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | $15.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $3.72 |
| 52 Week High | $8.97 | $8.74 |
Technical Indicators
Market Signals| Indicator | WHF | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 49.76 |
| Support Level | $6.80 | $5.28 |
| Resistance Level | $7.17 | $5.92 |
| Average True Range (ATR) | 0.17 | 0.27 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 64.94 | 56.62 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.